Navigation Links
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes (ACS), preclinical data evaluating rNAPc2 in mouse models of colorectal cancer, and preclinical data evaluating the mechanism of NU172, a short-acting, direct thrombin inhibiting aptamer, will be presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) taking place in Geneva, Switzerland, July 6-12, 2007.

The presentation details are as follows:
Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-016): Tissue Factor/Factor VIIa Inhibitor Reduces
Ischemia in Patients with NSTE-ACS: Final Results of the ANTHEM-TIMI
32 Trial

Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-067): Discovery of a Potent, Direct Thrombin
Inhibiting Aptamer

Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-072): Pharmacokinetic/Pharmacodynamic Profile of a
Novel Aptamer Direct Thrombin Inhibitor in Cynomolgus Monkeys and
Yorkshire Pigs Following a Single IV Bolus Administration

Date/Time: Monday, July 9, 2007, 10:00 a.m. CEST
Oral Presentation (O-M-001): rNAPc2, a Novel Inhibitor of Tissue
Factor/Factor VIIa Complex, Synergizes with 5-FU or Bevacizumab in a
Mouse Model of Colorectal Cancer

Date/Time: Tuesday, July 10, 2007, 5:30 p.m. CEST
Poster Session (P-T-509): rNAPc2, a Novel Inhibitor of Tissue
Factor/Factor VIIa Complex, Suppresses Liver and Lung Metastases in Mouse
Models of Colorectal Cancer

About NuveloNuvelo, Inc. i s dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and preclinical research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patien ts in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

SOURCE Nuvelo, Inc.
-0- 07/05/2007
/CONTACT: Nicole Foderaro, Director, Corporate Communications & IR of
Nuvelo, Inc., +1-650-517-8472, nfoderaro@nuvelo.com; or Carolyn Bumgardner
Wang of WeissComm Partners, Inc., +1-415-225-5050,
carolyn@weisscommpartners.com, for Nuvelo, Inc./
/Web site: http://www.nuvelo.com /
(NUVO)



'"/>




Related medicine technology :

1. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
2. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By ... 2014 - 2025" report to their offering. ... The Latin American pharmaceutical contract ... by 2025 Low drug registration cost in Latin ...
(Date:4/19/2017)... 19, 2017 Global Surgical Drainage Device Market: ... used to remove excess liquid and air. The fluid ... bile or lymph. Surgical drains are used in a ... orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common ... prevent accumulation of fluid e.g. blood or pus. Surgical ...
(Date:4/19/2017)... April 19, 2017 ... immune response in pets such as canine, avian ... of various types such as Attenuated Live Vaccines, ... DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines ... or bacteria, which have been weakend under laboratory ...
Breaking Medicine Technology:
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in ... a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the ...
(Date:4/28/2017)... San Mateo, CA (PRWEB) , ... April 28, 2017 , ... ... Bay Area cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to ... tags allow interested persons to bookmark and read organized content on topics such as ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):